Announcement

Collapse
No announcement yet.

Landmark TB Trial Identifies Shorter-Course Treatment Regimen

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • Landmark TB Trial Identifies Shorter-Course Treatment Regimen

    October 21, 2020

    Results from an international, randomized, controlled clinical trial indicate that a four-month daily treatment regimen containing high-dose, or “optimized,” rifapentine with moxifloxacin is as safe and effective as the existing standard six-month daily regimen at curing drug-susceptible tuberculosis (TB) disease. This regimen is the first successful short-course treatment regimen for drug-susceptible TB disease in almost 40 years.

    https://www.niaid.nih.gov/news-event...atment-regimen
Working...
X